Agreements reached under this partnership
Business alliance agreement- 1
Our company will conduct sales activities targeting medical institutions in Japan through pharmaceutical wholesalers, medical device wholesalers and other channels.
- 2
Craif株式会社 will provide タウンズ with technical support and other assistance necessary to supply MySignal and the pancreatic cancer SaMD currently under development by Craif株式会社.
- 3
Our company and Craif株式会社 will jointly conduct marketing for MySignal and the pancreatic cancer SaMD currently under development by Craif株式会社.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
At this time, we believe that the execution of this agreement will have a minor impact on our results. If it becomes clear that the agreement will have a material impact, we will promptly disclose the relevant information.
| Item | Details |
|---|---|
| Name of alliance partner | Craif株式会社 |
| Alliance partner's business activities | Research and development of next-generation tests for the early detection of diseases, primarily in the cancer field, and the realization of personalized medicine, as well as provision of the MySignal® urine-based cancer risk test |
| Alliance partner's location | Shinjuku-ku, Tokyo |
| Type of alliance | Business alliance agreement |
| Details of the alliance | Our company will conduct sales activities targeting medical institutions in Japan through pharmaceutical wholesalers, medical device wholesalers and other channels., Craif株式会社 will provide タウンズ with technical support and other assistance necessary to supply MySignal and the pancreatic cancer SaMD currently under development by Craif株式会社., Our company and Craif株式会社 will jointly conduct marketing for MySignal and the pancreatic cancer SaMD currently under development by Craif株式会社. |
| Contract Period | The exclusive distribution rights for the pancreatic cancer SaMD will initially run until the end of June of the year following the year in which sales commence. The term will be renewed upon satisfaction of certain conditions. |
| Contract Date | 8 July 2026 |
| Impact on Business Performance | At this time, we believe that the execution of this agreement will have a minor impact on our results. If it becomes clear that the agreement will have a material impact, we will promptly disclose the relevant information. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand sales and achieve greater market penetration for Craif株式会社 products, thereby maximizing the business growth and earnings of both parties.